Pivot Just Got an FDA Update—Here’s What Actually Changed

The Pivot Insulin Delivery System has received another FDA decision, just months after its initial clearance. On September 2, 2026, the FDA found Modular Medical's latest Pivot submission substantially equivalent through the traditional 510(k) pathway. The new action does not introduce an entirely different pump. Instead, it clears software enhancements designed to give users more flexibility in bolus dosing, improve the user interface, and expand customization. For clinicians following diabetes technology, that distinction matters because the September decision builds on the Pivot platform cleared earlier in 2026 rather than replacing it.

Table of Contents

• What changed with the September FDA decision?
• How does Pivot work?
• Where does Pivot fit among insulin pumps?
• What should clinicians and patients consider?
• Conclusion
• Frequently Asked Questions

What Changed With the Pivot FDA Clearance?

The original Pivot system received FDA clearance on April 8, 2026, under 510(k) K253534. That clearance covered a prescription insulin pump for adults 18 years and older who require insulin. The FDA documentation states that the system is compatible with Humalog U-100 rapid-acting insulin, with insulin lispro identified as an alternative.

Then came a second submission. The FDA received K262153 on June 26, 2026, and issued its substantially equivalent decision on September 2. Like the earlier submission, it went through the traditional 510(k) process and remained classified as an insulin infusion pump under product code LZG.

So, what actually changed?

According to Modular Medical's announcement following the decision, the new clearance covers software enhancements. These include more flexibility and customization for bolus dosing, improvements to the user interface, and other software upgrades. Perhaps the most notable change is the ability to customize how much insulin is delivered with each button push.

Therefore, clinicians should not interpret the September action as clearance of a completely new generation of Pivot hardware. Rather, it represents an incremental expansion of the existing platform's functionality.

That distinction is important when discussing the device with patients. FDA substantial equivalence means the agency determined the submitted device is sufficiently comparable to a legally marketed predicate for the purposes of the 510(k) pathway. It should not be interpreted as evidence that Pivot is clinically superior to other available pumps.

How the Pivot Insulin Delivery System Works

Pivot is designed as a tubeless patch pump providing continuous subcutaneous insulin infusion. It delivers both basal and bolus insulin and uses a wearable design intended for approximately three days of use before the disposable components are changed.

The pump itself is reusable. FDA documentation for the April clearance describes a pump/controller intended for up to 90 days of use, while the infusion set has an intended use period of 80 hours. A reusable inserter is also part of the system.

An iOS app is used to configure the basal delivery schedule. However, once that schedule has been programmed, insulin-delivery functions are controlled through the pump's own user interface. The device can therefore continue operating autonomously after programming.

The September update makes that physical interface more flexible. In particular, customizable insulin delivery with each button push may allow prescribed bolus regimens to be adapted more easily to individual needs. Still, dosing decisions must follow the patient's prescribed treatment plan.

Pivot also differs from many advanced pumps because it does not currently function as a closed-loop automated insulin delivery system. According to the Association of Diabetes Care & Education Specialists' device information, Pivot does not integrate with a continuous glucose monitor and does not provide automatic correction boluses.

That makes understanding the device category especially important. Diabetes In Control's diabetes technology comparison guide explains how traditional pumps, patch pumps, CGMs, and hybrid closed-loop systems differ in their features and clinical roles.

Where Pivot Fits in Today's Insulin Pump Landscape

The insulin pump market has increasingly moved toward automated insulin delivery. These systems typically combine a pump, CGM, and algorithm to adjust insulin delivery based on glucose data. As Diabetes In Control has previously reported, automated insulin delivery is also expanding into type 2 diabetes, widening the population that clinicians may consider for pump therapy.

However, greater automation can also mean greater complexity. Some patients may want pump therapy without needing every advanced feature available in an automated system.

That is where Pivot takes a different approach to insulin delivery. Its current design emphasizes tubeless insulin delivery, a relatively simple interface, basal programming, and user-initiated boluses rather than CGM-driven automated dosing.

Consequently, comparisons with automated pumps require some care. Pivot's value proposition is not currently centered on closed-loop automation. Instead, Modular Medical says it aims to provide a simpler pathway from multiple daily injections to pump therapy.

That approach could be relevant for adults who find traditional pump technology intimidating or unnecessarily complicated. However, patient preference alone is not enough to determine whether a particular system is appropriate. Insulin requirements, glucose patterns, dexterity, training needs, insurance coverage, lifestyle, and willingness to interact with a device all matter.

For clinicians, the latest clearance therefore adds another feature set to consider rather than changing the fundamental pump-selection process.

What the FDA Update Means for Clinical Conversations

The September clearance gives Pivot's insulin delivery platform more customization options, but careful patient selection and education remain essential.

First, clinicians should explain what the device does and does not automate. Patients familiar with modern CGM-connected pumps may assume that every patch pump automatically adjusts insulin based on glucose readings. Pivot currently does not provide that functionality.

Second, customizable button-based bolusing may make the interface more adaptable. Nevertheless, patients still need clear instructions regarding basal settings, mealtime dosing, correction doses, site changes, and what to do when insulin delivery is interrupted.

Third, clinicians should consider whether simplicity itself could improve adherence for certain patients. A feature-rich automated system may be valuable for one person, while another may prefer fewer steps and controls.

Finally, real-world experience will remain important. Modular Medical announced commercial availability and initial shipments in June 2026, while the company has described a broader commercial launch planned for the fourth quarter.

Therefore, clinicians evaluating Pivot should separate regulatory clearance from comparative clinical evidence. The new FDA decision confirms clearance of the submitted enhancements. It does not establish that Pivot produces better glycemic outcomes than automated insulin delivery systems or other pumps.

Conclusion

The latest FDA action is best understood as an update to an already-cleared platform. Pivot first received FDA clearance in April 2026, while the September 2 decision covers software enhancements that add bolus customization, user-interface improvements, and additional software upgrades.

For clinicians, the practical question is how those features fit an individual patient's needs. Pivot offers tubeless basal and bolus insulin delivery without the CGM integration and closed-loop automation found in many newer systems. As a result, its place in diabetes care may depend less on having the most automation and more on whether its simpler approach makes pump therapy practical for people who might otherwise remain on multiple daily injections.

Frequently Asked Questions

What is the Pivot Insulin Delivery System?

Pivot is a prescription tubeless insulin patch pump from Modular Medical. It provides continuous subcutaneous basal insulin delivery and user-initiated bolus dosing for adults who require insulin.

What did the FDA clear in September 2026?

The September clearance covers software enhancements, including greater bolus-dose customization, an enhanced user interface, and other software upgrades.

Was Pivot already FDA cleared?

Yes. The first Pivot 510(k), K253534, received a substantially equivalent decision on April 8, 2026. A second submission, K262153, received its decision on September 2, 2026.

Does Pivot automatically adjust insulin using CGM readings?

No. Current device information indicates that Pivot does not integrate with a CGM and does not offer closed-loop functionality or automatic correction boluses.

Does the latest FDA clearance mean Pivot is better than other insulin pumps?

No. A 510(k) substantial equivalence decision does not establish clinical superiority over competing pumps. Clinicians should consider the patient's insulin needs, desired level of automation, ability to operate the device, lifestyle, coverage, and treatment goals when evaluating pump options.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.